{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:19:36Z","timestamp":1791404376390,"version":"4.3.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s11894-017-0540-6","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T07:06:50Z","timestamp":1485328010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors"],"prefix":"10.1007","volume":"19","author":[{"given":"Peyton","family":"Cramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Bresalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,25]]},"reference":[{"key":"540_CR1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1078155214538087","volume":"21","author":"J Lu","year":"2014","unstructured":"Lu J, Lee-Gabel L, Nadeau MC, et al. Clinical evaluation of compounds targeting PD-1\/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract. 2014;21:451\u201367.","journal-title":"J Oncol Pharm Pract"},{"key":"540_CR2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1060028014528152","volume":"48","author":"SP Merrill","year":"2014","unstructured":"Merrill SP, Reynolds P, Kalra A, et al. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann Pharmacother. 2014;48:806\u201310.","journal-title":"Ann Pharmacother"},{"key":"540_CR3","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci. 2002;99:12293\u20137.","journal-title":"Proc Natl Acad Sci"},{"key":"540_CR4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"540_CR5","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455\u201365.","journal-title":"N Engl J Med"},{"key":"540_CR6","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889\u201394.","journal-title":"J Clin Oncol"},{"key":"540_CR7","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/annonc\/mdw181","volume":"27","author":"G Manson","year":"2016","unstructured":"Manson G, Norwood J, Marabelle A, et al. Biomarkers associated with checkpoint inhibitors. Ann Oncol. 2016;27:1199\u2013206.","journal-title":"Ann Oncol"},{"key":"540_CR8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","volume":"10","author":"L Marthey","year":"2016","unstructured":"\u2022\u2022 Marthey L, Mateus C, Mussini C, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohn\u2019s Colitis. 2016;10:395\u2013401. This study provides common laboratory, endoscopic, and histologic findings associated with anti-CTLA-4 gastrointestinal adverse events.","journal-title":"J Crohn\u2019s Colitis"},{"key":"540_CR9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"540_CR10","doi-asserted-by":"crossref","unstructured":"Gonzalez-Cao M, Boada A, Teixid\u00f3 C, et al. Fatal gastrointestinal toxicity with ipilimumab after BRAF\/MEK inhibitor combination in a melanoma patient achieving pathological complete response. Oncotarget 2016;7:56619\u201356627.","DOI":"10.18632\/oncotarget.10651"},{"key":"540_CR11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.cgh.2015.12.028","volume":"14","author":"EC Verschuren","year":"2016","unstructured":"Verschuren EC, Eertwegh AJ, Wonders J, et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol. 2016;14:836\u201342.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"540_CR12","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","volume":"24","author":"KE Beck","year":"2016","unstructured":"Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2016;24:2283\u20139.","journal-title":"J Clin Oncol"},{"key":"540_CR13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","volume":"45","author":"TK Eigentler","year":"2016","unstructured":"Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7\u201318.","journal-title":"Cancer Treat Rev"},{"key":"540_CR14","unstructured":"Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun; 2010;10:11."},{"key":"540_CR15","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.4049\/jimmunol.163.2.1081","volume":"163","author":"K Ina","year":"2009","unstructured":"Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn\u2019s disease T cells to multiple apoptotic signals is associated with a Bcl-2\/Bax mucosal imbalance. J Immunol. 2009;163:1081\u201390.","journal-title":"J Immunol"},{"key":"540_CR16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2012.06.039","volume":"143","author":"HS Souza","year":"2012","unstructured":"Souza HS, West GA, Rebert N, et al. Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn\u2019s disease. Gastroenterology. 2012;143:1017\u201326.e9.","journal-title":"Gastroenterology"},{"key":"540_CR17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.it.2010.12.007","volume":"32","author":"MH Shaw","year":"2011","unstructured":"Shaw MH, Kamada N, Warner N, et al. The ever-expanding function of NOD2: autophagy, viral recognition, and T cell activation. Trends Immunol. 2011;32:73\u20139.","journal-title":"Trends Immunol"},{"key":"540_CR18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12885-015-1074-7","volume":"15","author":"O Venditti","year":"2015","unstructured":"Venditti O, Lisi DD, Caricato M, et al. Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis. BMC Cancer. 2015;15:87.","journal-title":"BMC Cancer"},{"key":"540_CR19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1053\/j.gastro.2011.03.061","volume":"141","author":"B Pariente","year":"2011","unstructured":"Pariente B, Mocan I, Camus M, et al. Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn\u2019s disease. Gastroenterology. 2011;141:217\u201326.","journal-title":"Gastroenterology"},{"key":"540_CR20","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1136\/gutjnl-2013-305671","volume":"63","author":"IJ Fuss","year":"2014","unstructured":"Fuss IJ, Joshi B, Yang Z, Degheidy H, et al. IL-13R\u03b12-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of ulcerative colitis. Gut. 2014;63:1728\u201336.","journal-title":"Gut"},{"key":"540_CR21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/his.12263","volume":"64","author":"RM Feakins","year":"2013","unstructured":"Feakins RM. Ulcerative colitis or Crohn\u2019s disease? Pitfalls and problems. Histopathology. 2013;64:317\u201335.","journal-title":"Histopathology"},{"key":"540_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","volume":"13","author":"HS Souza","year":"2015","unstructured":"Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2015;13:13\u201327.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"540_CR23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","volume":"37","author":"AM Giacomo","year":"2010","unstructured":"Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010;37:499\u2013507.","journal-title":"Semin Oncol"},{"key":"540_CR24","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","volume":"31","author":"KW Kim","year":"2013","unstructured":"Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Investig New Drugs. 2013;31:1071\u20137.","journal-title":"Investig New Drugs"},{"key":"540_CR25","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","volume":"57","author":"DE Kleiner","year":"2012","unstructured":"Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57:2233\u201340.","journal-title":"Dig Dis Sci"},{"key":"540_CR26","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.24481","volume":"54","author":"A Suzuki","year":"2011","unstructured":"Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931\u20139.","journal-title":"Hepatology"},{"key":"540_CR27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1024\/0040-5930\/a000149","volume":"68","author":"MC Sulz","year":"2011","unstructured":"Sulz MC, Gerlach TJ. Autoimmune hepatitis. Ther Umsch. 2011;68:189\u201394.","journal-title":"Ther Umsch"},{"key":"540_CR28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.semdp.2006.11.001","volume":"23","author":"AA Suriawinata","year":"2006","unstructured":"Suriawinata AA, Thung SN. Acute and chronic hepatitis. Semin Diagn Pathol. 2006;23:132\u201348.","journal-title":"Semin Diagn Pathol"},{"key":"540_CR29","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1056\/NEJMra0805786","volume":"360","author":"MR Lucey","year":"2009","unstructured":"Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360:2758\u201369.","journal-title":"N Engl J Med"},{"key":"540_CR30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol EA, Borriello F, Schweitzer A, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541\u20137.","journal-title":"Immunity"},{"key":"540_CR31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.humimm.2014.02.020","volume":"75","author":"YH Lee","year":"2014","unstructured":"Lee YH, Kim J, Seo YH, et al. CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: a meta-analysis. Hum Immunol. 2014;75:414\u201321.","journal-title":"Hum Immunol"},{"key":"540_CR32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130142","volume":"10","author":"L Carbognin","year":"2015","unstructured":"Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS ONE. 2015;10, e0130142.","journal-title":"PLoS ONE"},{"key":"540_CR33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"540_CR34","doi-asserted-by":"crossref","first-page":"08","DOI":"10.1186\/1479-5876-12-S1-O8","volume":"12","author":"MA Postow","year":"2014","unstructured":"Postow MA, Cardona DM, Taube JM, et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab. J Transl Med. 2014;12 Suppl 1:08.","journal-title":"J Transl Med"},{"key":"540_CR35","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/CMR.0000000000000252","volume":"26","author":"B Baroudjian","year":"2016","unstructured":"Baroudjian B, Lourenco N, Pag\u00e8s C, et al. Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Res. 2016;26:308\u201311.","journal-title":"Melanoma Res"},{"key":"540_CR36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1479-5876-11-75","volume":"11","author":"V Shahabi","year":"2013","unstructured":"\u2022 Shahabi V, Berman D, Chasalow SD, et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J Transl. 2013;11:75. Alterations in a number of biomarkers have been correlated with both treatment efficacy and the development of gastrointestinal toxic events of immune checkpoint inhibitors. This paper suggests that gene expression profiling could play an important role in future treatment decisions and prevention of irAEs.","journal-title":"J Transl"},{"key":"540_CR37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","volume":"3","author":"AA Tarhini","year":"2015","unstructured":"Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3:39.","journal-title":"J Immunother Cancer"},{"key":"540_CR38","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/gut.42.6.788","volume":"42","author":"J-F Quinton","year":"1998","unstructured":"Quinton J-F, Sendid B, Duthilleul P, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788\u201391.","journal-title":"Gut"},{"key":"540_CR39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"\u2022 V\u00e9tizou M, Pitt JM, Daill\u00e8re R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079\u201384. Understanding the role of the gut microbiota in CTLA-4 blockade is critical in both treatment efficacy and the development of adverse events. Certain commensals might serve as anticancer probiotics, while others might even antagonize anticancer efficacy.","journal-title":"Science"},{"key":"540_CR40","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1007\/BF01303168","volume":"38","author":"F Kuroki","year":"1993","unstructured":"Kuroki F, Iida M, Tominaga M, et al. Multiple vitamin status in Crohn\u2019s disease. Dig Dis Sci. 1993;38:1614\u20138.","journal-title":"Dig Dis Sci"},{"key":"540_CR41","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/ajcn\/29.12.1333","volume":"29","author":"JJ Ellestad-Sayed","year":"1976","unstructured":"Ellestad-Sayed JJ, Nelson RA, Adson MA, et al. Pantothenic acid, coenzyme A, and human chronic ulcerative and granulomatous colitis. Am J Clin Nutr. 1976;29:1333\u20138.","journal-title":"Am J Clin Nutr"},{"key":"540_CR42","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1038\/ncomms10391","volume":"7","author":"K Dubin","year":"2016","unstructured":"Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391.","journal-title":"Nat Commun"},{"key":"540_CR43","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234.","journal-title":"JAMA Oncol"},{"key":"540_CR44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40425-015-0064-2","volume":"3","author":"AD Bostwick","year":"2015","unstructured":"Bostwick AD, Salama AK, Hanks BA. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer. 2015;3:19.","journal-title":"J Immunother Cancer"},{"key":"540_CR45","unstructured":"Tobias L. A briefing report on autoimmune diseases and AARDA: past, present, and future. Eastpointe: American Autoimmune Related Diseases Association (AARDA) 2010."},{"key":"540_CR46","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Retrieved August 1, 2016, from http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf . 2010."},{"key":"540_CR47","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/1078-0432.CCR-09-1024","volume":"15","author":"J Weber","year":"2009","unstructured":"Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:559.","journal-title":"Clin Cancer Res"},{"key":"540_CR48","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/01.cji.0000177999.95831.7b","volume":"28","author":"CS Hinrichs","year":"2005","unstructured":"Hinrichs CS, Palmer DC, Rosenberg SA, et al. Glucocorticoids do not inhibit antitumor activity of activated CD8 T cells. J Immunother. 2005;28:517\u201324.","journal-title":"J Immunother"},{"issue":"10","key":"540_CR49","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","volume":"21","author":"JS Weber","year":"2016","unstructured":"Weber JS, Postow M, Lao CD, et al. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist. 2016;21(10):1230\u201340.","journal-title":"Oncologist"},{"key":"540_CR50","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1007\/s10620-008-0641-z","volume":"54","author":"RL Johnston","year":"2009","unstructured":"Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2009;54:2538\u201340.","journal-title":"Dig Dis Sci"},{"key":"540_CR51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/CMR.0b013e32835fb524","volume":"23","author":"C Pag\u00e8s","year":"2013","unstructured":"Pag\u00e8s C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013;23:227\u201330.","journal-title":"Melanoma Res"},{"key":"540_CR52","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/ajg.2013.294","volume":"108","author":"LE Targownik","year":"2013","unstructured":"Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol. 2013;108:1835\u201342.","journal-title":"Am J Gastroenterol"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-017-0540-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-017-0540-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-017-0540-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T22:51:00Z","timestamp":1692658260000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-017-0540-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["540"],"URL":"https:\/\/doi.org\/10.1007\/s11894-017-0540-6","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"article-number":"3"}}